Edgar Filing: bluebird bio, Inc. - Form 4

bluebird bio Form 4	o, Inc.											
May 03, 2017												
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549										OMB Number:	3235-0287	
Section 16. Form 4 or Form 5 Filed pursuant to Section 1				NGES IN BENEFICIAL OWN SECURITIES 16(a) of the Securities Exchange						Expires: Estimated a burden hour response		
obligations may continue. See InstructionSection 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 1(b).												
(Print or Type Responses)												
Davidson David Symbol				uer Name and Ticker or Trading I Ird bio, Inc. [BLUE]					5. Relationship of Reporting Person(s) to Issuer			
(Last)	(First) (N	Middle)		of Earliest Transaction					(Check all applicable)			
									below)	ive title Other (specify below) ef Medical Officer		
				mendment, Date Original Month/Day/Year)					6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person			
CAMBRIDGE, MA 02142 — Form filed by More than One Reporting Person												
(City)		(Zip)		le I - Non				-	ired, Disposed of,	or Beneficiall	y Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Yansaction Date 2A. Deemed onth/Day/Year) Execution Date, if any (Month/Day/Year)			(A) or				5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6.7. Nature ofOwnershipIndirectForm:BeneficialDirect (D)Ownershipor Indirect(Instr. 4)(I)(Instr. 4)		
Common	05/01/2015					Amount		Price		D		
Stock	05/01/2017			М		3,000	А	\$ 2.09	20,177	D		
Common Stock	05/01/2017			S <u>(1)</u>		1,010	D	\$ 87.5792 (2)	19,167	D		
Common Stock	05/01/2017			S <u>(1)</u>		990	D	\$ 88.6096 (<u>3)</u>	18,177	D		
Common Stock	05/01/2017			S <u>(1)</u>		1,000	D	\$ 90.03 (4)	17,177	D		

Edgar Filing: bluebird bio, Inc. - Form 4

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transactic Code (Instr. 8)	5. Number opf Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)		8. I Dei Sec (Ini
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock Option (right to buy)	\$ 2.09	05/01/2017		М	3,000	(5)	04/13/2022	Common Stock	3,000	

Reporting Owners

Reporting Owner Name / Address	Relationships							
	Director	10% Owner	Officer	Other				
Davidson David C/O BLUEBIRD BIO, INC. 60 BINNEY STREET CAMBRIDGE, MA 02142			Chief Medical Officer					
Signatures								

/s/Jason F. Cole, Attorney-in-Fact

05/03/2017

Date

**Signature of Reporting Person

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 12, 2016.

The range of prices for the transaction reported on this line was \$87.10 to \$88.00. The average weighted price was \$87.5792. The

(2) reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

Edgar Filing: bluebird bio, Inc. - Form 4

The range of prices for the transaction reported on this line was \$88.15 to \$89.10. The average weighted price was \$88.6096. The(3) reporting person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

The range of prices for the transaction reported on this line was \$90.00 to \$90.05. The average weighted price was \$90.03. The reporting
 (4) person will provide, upon request by the SEC, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

(5) This option vests over a four-year period, at a rate of twenty-five percent (25%) on February 13, 2013 and in 36 equal monthly installments thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.